Effects of Nurse Navigators on Health Outcomes of Lymphoma Patients

November 2018 Vol 9, NO 11
Pei-Hua Wu
Chi Mei Medical Center
Liouying, Taiwan
Shu Chan Chang
Cancer Center
Chi Mei Medical Center
Liouying, Taiwan
Wen-Tsung Huang
Cancer Center
Chi Mei Medical Center
Liouying, Taiwan
Chao-Jung Tsao
Cancer Center
Chi Mei Medical Center
Liouying, Taiwan

Background: Lymphoma has the highest prevalence among all cancer types in Taiwan. Care coordination has received increased attention because it critically affects patient safety and care quality across services.

Objectives: To examine and evaluate the effect of adopting a nurse navigator intervention for newly diagnosed lymphoma patients.

Methods: In this retrospective study, 212 lymphoma patients were recruited between January 2009 and December 2013. The experimental group comprised 115 patients who had received nurse navigator interventions. The nurse navigator coordinated the recruitment, liaison, and care plan implementation and conducted disease education, telephone consultations, follow-ups, and evaluations. The control group comprised 97 lymphoma patients. The patients in the control group had similar characteristics to those in the experimental group and received routine care.

Results: Adopting nurse navigator intervention in lymphoma care increased patient follow-up appointment compliance rates at 3 months (P = .007). The model also effectively reduced the patients’ 14-day readmission rate (P = .05). Furthermore, these improvements were statistically significant. The results also indicated an increased survival rate for patients receiving care for lymphoma. The nurse navigator intervention was superior to the traditional care received by the control group.

Conclusion: Adopting nurse navigator intervention in lymphoma care effectively enhanced clinical treatment adherence, increased survival rates, and reduced the 14-day readmission rate. This study provides evidence that standardized nurse navigator programs can improve patient outcomes in cancer care.

Related Articles
Assessment of Side Effects (SEs) Impacting Quality of Life (QOL) in Patients (Pts) Undergoing Treatment (tx) for Advanced Breast Cancer (ABC) in Clinical Practice: A Real-World (RW) Multicountry Survey
November 2022 Vol 13, No 11
To examine how SEs impacting QOL in pts with ABC are perceived.
Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non–Small-Cell Lung Cancer (NSCLC) Enrolled in VISION
November 2022 Vol 13, No 11
To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
November 2022 Vol 13, No 11
MF is a rare bone marrow cancer characterized by fibrosis, abnormal blood cell production, and dysregulated JAK/STAT signaling.1,2
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country